Skip to content
2000
Volume 16, Issue 8
  • ISSN: 1573-4129
  • E-ISSN: 1875-676X

Abstract

Background: Tamoxifen (Soltamox) is an antineoplastic agent and an estrogen receptor antagonist used to treat breast cancer, but have severe side effects such as hot flashes, vaginal discharge, etc. Dose monitoring is a necessity for optimum treatment, to prevent severe adverse effects. Methods: In this study, the solvent bar microextraction method (SBME) was used for preconcentration and microextraction coupled with High-performance liquid chromatography-ultraviolet (HPLC-UV) analysis of tamoxifen. Results: The limit of detection and limit of quantification were 13.3 and 40 μgL-1, respectively. The linear range was between 40 and 10000 μgL-1 with a correlation coefficient of 0.999. The enrichment factor was 169 and the relative standard deviation within-day and between-day were 3.6 and 4.0, respectively. Conclusion: The use of sensitive SBME method coupled with HPLC-UV analysis for detection of tamoxifen at trace level proved to be successful, offering a desirable preconcentration factor, and a costeffective and green set-up for determining its rate of elimination from cancer patients and wastewater.

Loading

Article metrics loading...

/content/journals/cpa/10.2174/1573412915666190523114036
2020-12-01
2025-09-15
Loading full text...

Full text loading...

/content/journals/cpa/10.2174/1573412915666190523114036
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test